Skip to main content

Advertisement

SpringerLink
Log in

Inflammatory bowel disease in children

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

  • Crohn’s disease and ulcerative colitis remain medically incurable conditions with potentially significant morbidity. The treatment of children with these conditions therefore should seek to reduce or eliminate symptoms, optimize nutritional status, promote normal growth and development, prevent complications, and minimize the potential psychologic effects of chronic illness. Treatment strategies must seek to both induce and maintain clinical remission. For all but the most mildly affected children with Crohn’s disease, a combination of nutritional and pharmacologic approaches is optimal. For those with ulcerative colitis, anti-inflammatory medication is necessary.

  • Moderate to severe Crohn’s disease acutely responds best to potent immunomodulatory therapy, eg, corticosteroids and infliximab. Either agent must be coupled with 6-mercaptopurine or azathioprine to maintain long-term remission and to minimize toxicity. Particular attention must be paid to limit the growth suppression and other toxic effects of corticosteroids. Elemental or semielemental enteral nutrition also can induce remission effectively, but relapse is common after primary nutritional therapy is discontinued, mandating concomitant pharmacologic therapy with either 6-mercaptopurine or azathioprine. The availability of 6-mercaptopurine/azathioprine metabolite testing allows optimization of immunomodulatory therapy, detection of noncompliance, and avoidance of potentially dangerous toxicity.

  • Mild ulcerative colitis acutely responds to treatment with a 5-aminosalicylate medication. Long-term remission frequently can be maintained with the same medication. Moderate to severe disease activity requires potent immunomodulatory therapy if colectomy is to be avoided.

  • Surgery is a potential cure for patients with ulcerative colitis, although the development of pouchitis after ileal pouch anal anastomosis is common and frequently requires long-term medical management. Surgery provides only palliative relief of complications in those with Crohn’s disease.

  • Emerging therapies, especially evolving biologic and probiotic agents, offer hope for better treatments in the years ahead.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Young RA, Vanderhoof JA: Nutrition in pediatric inflammatory bowel disease. Nutrition 2000, 16:78–80.

    Article  PubMed  CAS  Google Scholar 

  2. Reif S, Klein I, Lubin F, et al.: Pre-illness dietary factors in inflammatory bowel disease. Gut 1997, 40:754–760.

    Article  PubMed  CAS  Google Scholar 

  3. Loeschke K, Ueberschaer B, Pietsch A, et al.: Omega-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 1996, 41:2087–2094.

    Article  PubMed  CAS  Google Scholar 

  4. Belluzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996, 334:1557–1560.

    Article  Google Scholar 

  5. Calkins BM: A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989, 34:1841–1854.

    Article  PubMed  CAS  Google Scholar 

  6. Sutherland LR, Ramcharan S, Bryant H, Fick G: Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology 1990, 98:1123–1128.

    PubMed  CAS  Google Scholar 

  7. Evans JM, McMahon AD, Murray FE, et al.: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997, 40:619–622.

    PubMed  CAS  Google Scholar 

  8. Griffiths AM, Ohlsson A, Sherman PM, et al.: Metaanalysis of enteral nutrition as primary therapy of active Crohn’s disease. Gastroenterology 1995, 108:1056–1067. This meta-analysis of both pediatric and adult studies provides an evidenced-based answer to the question of efficacy of enteral nutrition versus corticosteroids in Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  9. Heuschkel RB, Menache CC, Megerian JT, et al.: Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr 2000, 31:8–15.

    Article  PubMed  CAS  Google Scholar 

  10. Wilchanski M, Sherman P, Pencharz P, et al.: Supplementary enteral nutrition maintains remission in pediatric Crohn’s disease. Gut 1996, 38:543–548.

    Google Scholar 

  11. Polk DB, Hattner JA, Kerner JA: Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn’s disease. JPEN J Parenter Enteral Nutr 1992, 16:499–504.

    PubMed  CAS  Google Scholar 

  12. Fell JM, Paintin M, Arnaud Battandier F, et al.: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in pediatric Crohn’s disease. Aliment Pharmacol Ther 2000, 14:281–284.

    Article  PubMed  CAS  Google Scholar 

  13. Kushner RF, Shapir J, Sitrin MD: Endoscopic, radiographic and clinical response to prolonged bowel rest and home parenteral nutrition in Crohn’s disease. JPEN Parenter Enteral Nutr 1986, 10:568–573.

    Article  CAS  Google Scholar 

  14. Rombeau JL, Barot LR: Preoperative total parenteral nutrition and surgical outcome in patients with inflammatory bowel disease. Am J Surg 1982, 143:139–143.

    Article  PubMed  CAS  Google Scholar 

  15. Sutherland LR, May GR, Schaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Int Med 1993, 118:540–549.

    PubMed  CAS  Google Scholar 

  16. Ferry GD, Kirschner BS, Grand RJ, et al.: Olsalazine versus sulfasalazine in mild to moderate childhood colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gatroenterol Nutr 1993, 17:32–38.

    Article  CAS  Google Scholar 

  17. Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997, 113:1465–1473.

    Article  PubMed  CAS  Google Scholar 

  18. Sutherland LR: Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 2000, 118:436–438.

    Article  PubMed  CAS  Google Scholar 

  19. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy in distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995, 9:293–300.

    Article  PubMed  CAS  Google Scholar 

  20. Sutherland LR: Topical treatment of ulcerative colitis. Med Clin North Am 1990, 74:119–131.

    PubMed  CAS  Google Scholar 

  21. Brattsand R: Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990, 4:407–414.

    Google Scholar 

  22. Brandt LJ: Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology 1982, 83:383–387.

    PubMed  CAS  Google Scholar 

  23. Sutherland L, Singleton J, Sessions J, et al.: Doubleblind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991, 32:1071–1075.

    PubMed  CAS  Google Scholar 

  24. Rutgeerts P, Hiele M, Geboes K, et al.: Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995, 108:1617–1621.

    Article  PubMed  CAS  Google Scholar 

  25. Greenbloom SL, Steinhart AH, Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn’s disease. Can J Gastroenterol 1998, 12:53–56.

    PubMed  CAS  Google Scholar 

  26. Turunen UM, Farkkila MA, Hakala K, et al.: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998, 115:1072–1078.

    Article  PubMed  CAS  Google Scholar 

  27. Markowitz J, Grancher K, Kohn N, et al.: 6-mercaptopurine and prednisone therapy for newly diagnosed pediatric Crohn’s disease: a prospective multicenter placebo-controlled clinical trial. Gastroenterology 2000, 119:895–902. This is the only prospective, placebo-controlled study conducted in pediatric patients that looked at and proved the efficacy of 6-mercaptopurine as a steroid-sparing agent and in maintaining remission in moderate and severe Crohn’s disease.

    Article  PubMed  CAS  Google Scholar 

  28. Markowitz J, Rosa J, Grancher K, et al.: Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990, 99:1347–1351.

    PubMed  CAS  Google Scholar 

  29. Baldassano RN, Han PD, Jeshion WC, et al.: Pediatric Crohn’s disease: risk factors for postoperative recurrence. Am J Gastroenterol 2001, 96:2169–2176.

    Article  PubMed  CAS  Google Scholar 

  30. Jeshion WC, Larsen KL, Jarvard AF: Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn’s disease in children. J Clin Gastroenterol 2000, 30:294–298.

    Article  PubMed  CAS  Google Scholar 

  31. Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000, 342:1627–1632.

    Article  PubMed  CAS  Google Scholar 

  32. Mack D, Young R, Kaufman S, et al.: Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J Pediatr 1998, 132:830–835.

    Article  PubMed  CAS  Google Scholar 

  33. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.

    Article  PubMed  CAS  Google Scholar 

  34. Brynskov J, Freund L, Rasmussen SN, et al.: A placebocontrolled, double-blind randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989, 321:845–850.

    Article  PubMed  CAS  Google Scholar 

  35. Treem WR, Hyams JS: Cyclosporine therapy for gastrointestinal disease. J Pediatr Gastroenterol Nutr 1994, 18:270–278.

    Article  PubMed  CAS  Google Scholar 

  36. Present DH, Lichtiger S: Efficacy of cyclosporine in treatment of fistulas in Crohn’s disease. Dig Dis Sci 1994, 39:374–380.

    Article  PubMed  CAS  Google Scholar 

  37. Bousvaros A, Kirshner BS, Werlin SL, et al.: Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000, 137:794–799.

    Article  PubMed  CAS  Google Scholar 

  38. Hyams JS, Markowitz J, Wyllie R: Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000, 137:192–196.

    Article  PubMed  CAS  Google Scholar 

  39. Kugathasan S, Werlin SL, Martinez A, et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000, 95:3189–3194.

    Article  PubMed  CAS  Google Scholar 

  40. Rutgeerts PJ, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761–769.

    Article  PubMed  CAS  Google Scholar 

  41. Hanauer SB, Rutgeerts PJ, Sandborn WJ: Maintenance infliximab (Remicade) is safe, effective and steroid sparing in Crohn’s disease. Preliminary results from the ACCENT I trial. Gastroenterology 2001, 120(suppl 1):A-21.

    Google Scholar 

  42. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  43. Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83–88.

    Article  PubMed  CAS  Google Scholar 

  44. Lewis LD, Benin A, Szumlanski CL, et al.: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997, 62:464–475.

    Article  PubMed  CAS  Google Scholar 

  45. Kirschner B: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813–821. A useful overview of side effects of 6-mercaptopurine/ azathioprine therapy and efficacy in pediatric patients with IBD.

    Article  PubMed  CAS  Google Scholar 

  46. Dubinsky MC, Lamothe S, Yang HY, et al.: Phamacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713.

    Article  PubMed  CAS  Google Scholar 

  47. Targan SR, Hanauer SB, van Deventer SJH, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-_ for Crohn’s disease. N Engl J Med 1997, 337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  48. Davies G, Evans CM, Whand WS, et al.: Surgery for Crohn’s disease in childhood: influence of site of disease and operative procedure on outcome. Br J Surg 1990, 77:891–894.

    Article  PubMed  CAS  Google Scholar 

  49. Telander RL, Schmeling DJ: Current surgical management of Crohn’s disease in childhood. Semin Pediatr Surg 1994, 3:19–27.

    PubMed  CAS  Google Scholar 

  50. Oliva L, Wyllie R, Alexander F, et al.: The results of strictureplasty in pediatric patients with multifocal Crohn’s disease. J Pediatr Gastroenterol Nutr 1994, 18:306–310.

    Article  PubMed  CAS  Google Scholar 

  51. Hyams JS, Davis P, Grancher K, et al.: Clinical outcome of ulcerative colitis in children. J Pediatr 1996, 129:81–88.

    Article  PubMed  CAS  Google Scholar 

  52. Markowitz JF: Ulcerative colitis. In Pediatric Gastrointestinal Disease, edn 2. Edited by Wyllie R, Hyams J. Philadelphia: W B Saunders Co; 1999:419–432.

    Google Scholar 

  53. Fonkalsond EW, Thakur A, Beanes S: Ileoanal pouch procedures in children. J Pediatr Surg 2001, 36:1689–1692.

    Article  Google Scholar 

  54. Sandborn WJ, Feagan B, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571): a randomized double-blind, placebo-controlled trial. Gastroenterology 2001, 120:1330–1338.

    Article  PubMed  CAS  Google Scholar 

  55. Evans RC, Clarke L, Heath P, et al.: Treatment of ulcerative colitis with an engineered human anti-TNF-a antibody CDP571. Aliment Pharmacol Ther 1997, 11:1031–1035.

    Article  PubMed  CAS  Google Scholar 

  56. Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 12:1088–1094.

    Article  Google Scholar 

  57. Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999, 117:1271–1277.

    Article  PubMed  CAS  Google Scholar 

  58. Fedorack RN, Gangl A, Elson CO, et al.: Safety, tolerance, efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn’s disease [abstract]. Gastroenterology 1998, 114:A974.

    Article  Google Scholar 

  59. Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352–1355.

    Article  PubMed  CAS  Google Scholar 

  60. Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 1999, 117:58–64.

    Article  PubMed  CAS  Google Scholar 

  61. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalazine for treatment of ulcerative colitis: a randomized trial. Lancet 1999, 354:635–639.

    Article  PubMed  CAS  Google Scholar 

  62. Gionchetti P, Rizello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305–309.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Gastroenterology and Nutrition, North Shore-Long Island Jewish Health System, 300 Community Drive, 11030, Manhasset, NY, USA

    Mihaela Ringheanu MD & James Markowitz MD

Authors
  1. Mihaela Ringheanu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Markowitz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ringheanu, M., Markowitz, J. Inflammatory bowel disease in children. Curr Treat Options Gastro 5, 181–196 (2002). https://doi.org/10.1007/s11938-002-0040-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-002-0040-z

Keywords

Search

Navigation